- WKN: A0HGQF
- ISIN: DE000A0HGQF5
- Land: Deutschland
Nachricht vom 11.12.2019 | 09:30
MagForce AG: 'NanoTherm School' successfully enters its second round with Module B
MagForce AG: 'NanoTherm School' successfully enters its second round with
Berlin, Germany and Nevada, USA, December 11, 2019 - With "Module B - Advanced Course 1: - stereotactic Instillation" MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, conducted the second round of its 'NanoTherm School' in November. The application training series was launched in January 2019 to provide the highest quality of treatment through ongoing support for physicians and certify surgeons in the use of the innovative NanoTherm technology. Same as the first session, "Module A - The Basics", which took place at the end of January 2019, Module B, focusing on advanced techniques, was met with great excitement from participants.
The NanoTherm School is part of MagForce's roll-out strategy focusing on a broad geographic coverage to provide greater availability while also constantly working on further optimizing its therapy system and educating medical professionals in its use to provide brain tumor patients with the best care possible. The training concept of NanoTherm School was developed in close collaboration with Prof. Dr. Walter Stummer, PD Dr. Dr. Oliver Grauer, and Dr. Michael Schwake, University Hospital Münster, and PD Dr. Johannes Wölfer, Hufeland Klinikum GmbH Mühlhausen, drawing on their long-standing experience in the treatment of brain tumor patients with the NanoTherm therapy system.
Participants again included the team of Prof. Dr. med. habil. Jan-Peter Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus Clinic in Zwickau, with whom MagForce entered into a cooperation agreement in June 2019. Installation of the mobile treatment center was completed in summer. The NanoActivator is now ready for use at the clinic after receipt of final approval and and is now available for the treatment of patients with brain tumors.
Prof. Dr. med. habil. Jan-Peter Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus Clinic in Zwickau, added "Innovation is extremely important in medicine and has served our patients well. Obtaining the appropriate training in new technologies and techniques is a vital part of adopting these advances into our standard treatment regimens. Practical trainings such as MagForce's NanoTherm School are therefore very welcomed as they allow neurosurgeons to ease into the method while developing the necessary skills. Thanks to the excellent preparation and support of the MagForce team, as well as the opportunity to practice NanoTherm therapy in the most practical and extremely well-structured way, we are well prepared for the use of the therapy system at our clinic starting immediately. The use of new teaching methods for advanced technologies helps us to bring outstanding inventions to patients."
About NanoTherm School
The NanoTherm School is designed in three consecutive modules allowing participants to gain knowledge and understanding of MagForce's NanoTherm technology starting from basic application techniques (nanopasting) and building to advanced techniques and new surgical application forms in the final module (Module C). The practical section of the course is complemented by lectures on directly relevant aspects of NanoTherm therapy, as well as sample preparation and surgical videos. The equipment and facilities used during the course meet the requirements of today's state-of-the-art surgical equipment.
About MagForce AG and MagForce USA, Inc.
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com.
Barbara von Frankenberg
Communications & Investor Relations
End of Media Release
Issuer: MagForce AG
Key word(s): Health
|Phone:||+49 (0)30 308 380 0|
|Fax:||+49 (0)30 308 380 99|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange|
|EQS News ID:||932409|
|End of News||DGAP Media|
MagForce AG announces successful capital incre ...
MagForce AG announces successful capital incre ...
MagForce AG: 'NanoTherm School' successfully e ...
New hope for brain tumor patients in Saxony: P ...
MagForce AG Publishes Financial Results for th ...
UmweltBank AG mit deutlichem Kurspotenzial
Die UmweltBank AG, die als einzige Bank Deutschlands den Umweltgedanken in der Satzung verankert hat, präsentierte in den letzten Jahren beeindruckende Wachstumszahlen. Sowohl die Kundeneinlagen als auch das Kreditbuch legten um durchschnittlich gut 6,3 % zu. Seit seiner Gründung hat das Kreditinstitut stets positive Ergebnisse erzielt, zuletzt im Geschäftsjahr 2018 einen Jahresüberschuss in Höhe von 25,3 Mio. €. Wir haben ein Kursziel von 14,30 € je Aktie ermittelt, was deutlich oberhalb des aktuellen Kursniveaus liegt. Die Dividendenrendite liegt bei fast 3,0 %.
Der AKTIONÄR News
18. Januar 15:54 Amazon, Beyond Meat und Co: So geht es weiter
18. Januar 09:10 Wirecard: Darum setze ich auf die Aktie
18. Januar 08:25 Der Offenbarungseid des Olaf Scholz
22nd Annual Needham Growth Conference
15. Januar 2020
Original-Research: amalphi AG (von Sphene Capital GmbH): Buy
17. Januar 2020